세계의 급성 골수성 백혈병 치료제 시장 : 예측, 동향

Highlights:

The global acute myeloid leukemia (AML) treatments market should reach $6.1 billion by 2028 from $3.8 billion in 2023 at a compound annual growth rate (CAGR) of 10.0% for the forecast period of 2023 to 2028.

Targeted therapy segment of the global AML treatments market is expected to grow from $3.5 billion in 2023 to $5.6 billion in 2028 at a CAGR of 9.9% for the forecast period of 2023 to 2028.

Anthracycline drugs segment of the global AML treatments market is expected to grow from $141.3 million in 2023 to $239.8 million in 2028 at a CAGR of 11.2% for the forecast period of 2023 to 2028.

Report Scope:

This report aims to comprehensively study the market size of AML and treatments for a global market. Current and historical market revenues can be estimated based on treatment type, route of administration, end use, distribution channel and region.

Report Includes:

• 42 data tables and 57 additional tables
• An overview of the global market for acute myeloid leukemia (AML) treatment
• Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of AML market based on treatment type, route of administration type, end-users, distribution channel, region
• Coverage of various risk factors associated with AML, such as exposure to radiation or chemicals, genetic disorders, and weakened immune system
• Description of major treatment options for AML such as, chemotherapy, targeted therapy, and stem cell transplantation
• Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
• Detailed company profiles of major players in the market of the industry, including AbbVie, Daiichi Sankyo, GlaxoSmithKline PLC, Pfizer Inc. and Servier

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Methodology
• Information Sources
• Primary Research
• Secondary Research
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• This Report Highlights

Chapter 3 Market Overview and Definitions

• Overview
• Acute Myeloid Leukemia
• The Global Regulatory Structure for AML
• Pricing and Reimbursement for AML
• Therapies/Drugs to Treat AML
• FLT3 Inhibitors
• IDH Inhibitors
• Apoptosis Stimulants
• DNA Methylation Inhibitors
• DNA Intercalators
• Angiogenesis Inhibitors
• DNA Synthesis Inhibitors

Chapter 4 Market Dynamics

• Market Drivers
• Growing Elderly Population
• Increasing Incidence and Prevalence
• Advancements in Molecular Diagnostics
• Minimal Residual Disease (MRD) Monitoring
• Gene Expression Profiling
• Fusion Gene Detection
• Liquid Biopsies
• R&D
• Regulatory Environment
• Personalized Medicine
• Collaborative Efforts
• Patient Advocacy and Awareness
• Market Opportunity
• Strategic Initiative
• Market Restraints
• High Costs
• Limited Treatment Options
• Treatment-related Toxicity and Adverse Effects
• Regulatory and Reimbursement Challenges

Chapter 5 Impact of COVID-19

• Introduction
• COVID-19 Impact on AML Treatments

Chapter 6 Market Breakdown by Region

• Market Overview and Discussion
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Market Breakdown by Treatment Type

• Market Overview and Discussion
• Targeted Therapy
• Anthracycline Drugs
• Other Chemotherapies
• Targeted Therapy
• Anthracycline Drugs
• Other Chemotherapies

Chapter 8 Market Breakdown by Route of Administration

• Market Overview and Discussion
• Intravenous (IV) Administration
• Oral Administration
• Intravenous (IV) Administration

Chapter 9 Market Breakdown by Product

• FLT3 Inhibitors
• Apoptosis Stimulants
• Angiogenesis Inhibitors
• DNA Methylation Inhibitors
• DNA Synthesis Inhibitors
• DNA Intercalators

Chapter 10 ESG Development

• Introduction
• Environment
• Governance

Chapter 11 Emerging Trends and Technologies

• Introduction

Chapter 12 Competitive Landscape

• Overview
• Industry Scenario
• Company Shares

Chapter 13 Patent Analysis

• Patent Analysis by Manufacturer

Chapter 14 Pipeline Analysis

• Clinical Trail Scenario

Chapter 15 M&A and Venture Funding Outlook

• Introduction

Chapter 16 Company Profiles

• ABBVIE
• AMGEN INC.
• ASTELLAS PHARMA INC.
• BAYER AG
• BIOGEN
• BRISTOL MYERS SQUIBB
• DAIICHI SANKYO CO. LTD.
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• MERCK & CO. INC.
• NOVARTIS
• PFIZER INC.
• SANOFI
• SERVIER LABORATORIES
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter 17 Appendix: Acronyms